ARTICLE SUMMARY:
San Diego-based start-up Biolinq is developing a next-generation continuous glucose monitoring technology based on a sensor microarray that it says will be much smaller, less invasive, more reliable, and lower cost than existing CGM products.
Diabetes is a disease that comes with a very high daily burden. People with type 1 diabetes (T1D), whose bodies no longer produce the insulin they need to stay alive, must intensively manage their condition, checking their blood glucose and injecting insulin several times per day.
